$Novo-Nordisk A/S (NVO.US)$ When the market rises, this stock falls; when the market falls, this stock leads the decline—a classic underperformer.

$Novo-Nordisk A/S (NVO.US)$ Buy more as it falls, the drop is irrational

$Novo-Nordisk A/S (NVO.US)$ I don’t understand why it's falling

$Novo-Nordisk A/S (NVO.US)$ Still in the process of consolidation, unsure how much longer it will take

$Novo-Nordisk A/S (NVO.US)$ High-dose injections may surpass Eli Lilly and Co

$Novo-Nordisk A/S (NVO.US)$ NVO's strongest advantage right now is its clear lead in oral weight-loss medication. The next big expectation from the market is whether higher-dose weight-loss injections can deliver even more impressive weight reduction results. First, look at the 50-55 range. If it can achieve effects similar to Eli Lilly and Co, it will likely reach at least 70-80.

$Novo-Nordisk A/S (NVO.US)$ It should break 50 tonight

$Roblox (RBLX.US)$ The earnings are good, but the guidance is too conservative

$Novo-Nordisk A/S (NVO.US)$ There is a high probability that it will reach 45 next week

$Novo-Nordisk A/S (NVO.US)$ Today, there will be a minimum of 4-5%, with oral medications significantly outperforming Eli Lilly and Co